Bio-Rad (BIO) Q2 EPS Jumps 51%
Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and clinical diagnostics, posted its second quarter 2025 financial results on July 31, 2025. The most important news was a clear earnings and revenue beat: Adjusted earnings per share (non-GAAP) were $2.61 in Q2 2025, well above the $1.73 non-GAAP analyst consensus for Q2 2025. Non-GAAP revenue reached $651.6 million in Q2 2025 compared to the $615.2 million non-GAAP revenue expectation. Sales saw slight growth compared to the same period in 2024, with total net sales increasing by 2.1% in Q2 2025 versus Q2 2024, GAAP and non-GAAP gross margins declined in Q2 2025 compared to Q2 2024, and GAAP operating margin also declined, underlining persistent challenges despite headline results. Overall, the quarter showed strong top-line performance, steady innovation, and ongoing margin pressure amid ongoing industry and geopolitical headwinds.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Bio-Rad Laboratories specializes in the development and manufacturing of products for life science research and clinical diagnostics. Its tools and systems help scientists and healthcare professionals to conduct biological research and perform diagnostic testing for diseases and medical conditions.
Source Fool.com
